Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren’s Syndrome?

Ítems similars

• Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?
  per: Valérie Devauchelle-Pensec, et al.
  Publicat: (2015-01-01)
• Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögren’s Syndrome. Data at Enrollment in the Prospective ASSESS Cohort
  per: Gottenberg, Jacques-Eric, et al.
  Publicat: (2013)
• High-Grade Salivary-Gland Involvement, Assessed by Histology or Ultrasonography, Is Associated with a Poor Response to a Single Rituximab Course in Primary Sjögren’s Syndrome: Data from the TEARS Randomized Trial
  per: Cornec, Divi, et al.
  Publicat: (2016)
• Level of agreement between 2002 American–European Consensus Group and 2012 American College of Rheumatology classification criteria for Sjögren’s syndrome and reasons for discrepancies
  per: Cornec, Divi, et al.
  Publicat: (2014)
• Seasonal effect on fatigue, pain and dryness in primary Sjögren’s syndrome
  per: Duret, Pierre-Marie, et al.
  Publicat: (2020)